Summary
This prediction ended on 16.04.23 with a price of €0.95. The BUY prediction by kostojunior for iBio Inc. performed very badly with a performance of -38.59%. kostojunior has 100% into this predictioniBio is a listed biotechnology company with the ticker symbol iBio that focuses on developing novel plant-based biologics and vaccines to combat infectious diseases and other medical conditions. The company leverages its proprietary expression technology to rapidly produce high-quality proteins at a commercial scale, providing a cost-effective and scalable alternative to traditional manufacturing processes. iBio has strategic collaborations with leading pharmaceutical companies and is actively exploring partnerships to advance its product pipeline and expand its reach. The company is headquartered in Bryan, Texas, and is publicly traded on the NYSE American stock exchange.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| iBio Inc. | - | - | - |
| iShares Core DAX® | 2.749% | 4.620% | 17.121% |
| iShares Nasdaq 100 | 0.470% | -0.331% | 37.776% |
| iShares Nikkei 225® | -2.930% | -5.556% | 12.185% |
| iShares S&P 500 | 0.679% | 0.631% | 28.996% |
According to kostojunior what are the pros and cons of iBio Inc. for the foreseeable future?
Pros
Some uniques
Cons
Significant cyclical dependencies
Little known brand
Higher risks for its business
Comments by kostojunior for this prediction
In the thread iBio Inc. diskutieren
Kursziel geändert auf 3,0